Feedback Sought on Strengthening Capacity for Emergency Clinical Trials

The White House Office of Science and Technology Policy (OSTP) and National Security council recently released a Request for Information seeking ideas on strengthening the national capacity of clinical trial infrastructure and emergency clinical trials.

UNITE CO-CHAIRS’ CORNER: Announcing the Inaugural UNITE Progress Report

Today we published our first NIH UNITE Progress Report! Covering Fiscal Years 2021–2022, the UNITE Progress Report describes NIH’s actions to identify and address structural racism that may exist within the NIH and in the biomedical and behavioral research enterprise.

Follow-Up Career Stage Analyses of Applications Submitted During the Pandemic (Part 6)

We looked at applications broken down by career stage in June 2022. It was interesting to notice slowly increasing trends in the proportions of early stage investigator applications submitted by women and by underrepresented minorities. We repeat these career stage analyses here, specifically focusing on applications received between January 8 and September 7 in six consecutive years.

Center for Scientific Review 2022-2027 Strategic Plan

The Center for Scientific Review (CSR) announce the release of the CSR 2022-2027 Strategic Plan. CSR is entrusted with most of the peer review that enables NIH to support a broad range of biomedical research. Our primary goal, to ensure that peer review identifies the strongest, most promising science, depends upon an evaluation process that is fair, independent, expert, timely and free from inappropriate influences.

Another Look at Applications Submitted During the Pandemic (Part 5): A Focus on Career Stage

In earlier posts, we looked at the distributions of gender and race of designated principal investigators (PIs) of R01 and RPG applications submitted before and after the onset of the COVID-19 pandemic. Here we extend on our prior analyses by presenting R01-equivalent application data on PI characteristics of Early Stage Investigators (ESIs).

A Reflection on Impact

It’s worth reflecting that it has been more than two years since the COVID-19 pandemic began. Let’s look back to the months of early to mid-2020 when the nation (and the rest of the world) faced a “novel” coronavirus, one which we knew could be fatal and for which there was little knowledge about how it spreads and no known effective treatment, limited diagnostic tests, and no vaccine. How did NIH make fast and meaningful contributions to respond to the pandemic?

Reminder: NIH Will Continue to Accept Preliminary Data as Post-Submission Material Through January 2023 Councils

NIH will continue to accept a one-page update with preliminary data as post-submission materials for applications submitted for summer 2022 due dates, ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application.